BioVie (Nasdaq: BIVI) CEO Cuong Do on Near Term Catalysts in Parkinson’s, Long COVID, and Ascites
From Small Stocks, Big Money by RedChip Companies
February 24, 2026 · 10 min · Season 4 · Episode 7
About this episode
Cuong Do, CEO of BioVie, discusses the company's clinical-stage pipeline and upcoming milestones in treating Parkinson's, Long COVID, and ascites.
BioVie (Nasdaq: BIVI) President and CEO Cuong Do joins us for an exclusive investor interview discussing BioVie’s late-clinical-stage pipeline and upcoming milestones across neurodegeneration and liver disease.In our conversation, Cuong outlines why BioVie is targeting TNFα-mediated inflammation and insulin resistance with bezisterim (formerly NE3107), plus the company’s second program, BIV201, for refractory ascites, a high-mortality complication of liver cirrhosis with no FDA-approved drug therapies today.BioVie is positioning for multiple catalysts across a differentiated clinical-stage portfolio targeting large unmet needs in neurodegeneration and liver disease, supported by an experienced leadership team.Watch the full interview for management’s full roadmap, trial design insights, and how the company is thinking about value creation over the next 12 months.👉 BioVie is a client of RedChip. To learn more about BIVI and to read our full disclosure, visit: https://www.BIVIinfo.com#BIVI #BioVie #BiotechStocks #SmallCapStocks #Investing #Parkinsons #LongCOVID #Alzheimers #ClinicalTrials #HealthcareInvesting
People in this episode
Guest: Cuong Do
Topics covered
- Parkinson's
- Long COVID
- Ascites
- neurodegeneration
- liver disease
- biotech
- clinical trials
Keywords
- BioVie
- BIVI
- bezisterim
- BIV201
- clinical trials
- investing
- healthcare
Sponsors
RedChip
Mentioned in this episode
Organizations: BioVie
Products: bezisterim, BIV201
Places: Nasdaq
More episodes of Small Stocks, Big Money
- CEO Lavell Malloy on Brag House's (Nasdaq: TBH) Blockchain Sports Platform & Athlete Tokenization · June 9, 2026 · 6 min
- CEO James Foster on Virax Biolabs' (VRAX) Long COVID Diagnostic & US Market Entry · May 25, 2026 · 9 min
- Jeremy Schwartz CIO of WisdomTree ($WT): $165B AUM, Mega Trends & Why WT Is a Secular Growth Stock · May 20, 2026 · 9 min
- First Phosphate (FRSPF) CEO on Agnico's $94M Bet Leaves Only 2 Independents Standing · May 12, 2026 · 8 min
- Anixa Biosciences (ANIX): CEO on Breast Cancer Vaccine, Phase 2 Catalyst & Ovarian Cancer CAR-T Data · May 11, 2026 · 9 min
- CEO Brandon Robinson on Horizon Aircraft’s (HOVR) Commercial eVTOL Advantages · April 28, 2026 · 8 min
Explore listener stats, chart rankings, contacts and more on the Small Stocks, Big Money podcast page.